Modafinil In Debilitating Fatigue After Stroke 2
Lead PI: Prof Chris Levi and Dr Andrew Bivard
No. of Patients Currently Recruited: 94 No. of Patients Required: 300 – 400
MIDAS 2 is Phase III multicentre, prospective, randomised, placebo-controlled, double-blind study. The aim of the study is to compare the efficacy of 200mg modafinil taken once a day for 56 days, with a physically identical placebo in community dwelling patients who have experienced a stoke more than 3 months prior. Participants will be experience severe persisting fatigue as measured by a score of 60 or more the Multidimensional Fatigue Inventory (MFI). The study currently has 10 active sites in Australia.
ANZCTR Trial registration ID: ACTRN1261800060222